|
|
|
|
| LEADER |
01512nam a2200301 u 4500 |
| 001 |
EB001840099 |
| 003 |
EBX01000000000000001004088 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 245 |
0 |
0 |
|a Warfarin management in patients with atrial fibrillation
|h Elektronische Ressource
|b current practice study
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c March 2012, 2012
|
| 300 |
|
|
|a 1 PDF file (84 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Warfarin / therapeutic use
|
| 653 |
|
|
|a Thromboembolism / prevention & control
|
| 653 |
|
|
|a Patient Satisfaction
|
| 653 |
|
|
|a Atrial Fibrillation / complications
|
| 653 |
|
|
|a Atrial Fibrillation / drug therapy
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH optimal use report
|
| 500 |
|
|
|a "This report was prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH)"--T.p. verso
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK361753
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The objective of this current practice study was to explore the views and experiences of health care professionals and patients with atrial fibrillation regarding the use of warfarin and management of warfarin therapy for the prevention of thromboembolic events
|